ASX:GTG

Genetic Technologies Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Genetic Technologies (ASX:GTG) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying GTG stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Genetic Technologies, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

Genetic Technologies vs. (BUX) Stock

(BUX) (CNSX:BUX) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for (BUX) and Genetic Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(BUX)	0	0	0	0	N/A
Genetic Technologies	0	0	0	0	N/A

Valuation and Earnings

This table compares (BUX) and Genetic Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(BUX)	N/A	N/A	N/A	N/A	N/A
Genetic Technologies	$25,714.00	0.00	$-9,016,729.60	A$0.00	N/A

(BUX) has higher earnings, but lower revenue than Genetic Technologies.

Profitability

This table compares (BUX) and Genetic Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(BUX)	N/A	N/A	N/A
Genetic Technologies	N/A	N/A	N/A

Summary

Genetic Technologies beats (BUX) on 1 of the 1 factors compared between the two stocks.

Genetic Technologies vs. 12144 Stock

Genetic Technologies (ASX:GTG) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Genetic Technologies and 12144's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
12144	N/A	N/A	N/A

Valuation and Earnings

This table compares Genetic Technologies and 12144's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$25,714.00	0.00	C$-9,016,729.60	A$0.00	N/A
12144	N/A	N/A	N/A	N/A	N/A

12144 has lower revenue, but higher earnings than Genetic Technologies.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genetic Technologies and 12144, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0	0	0	0	N/A
12144	0	0	0	0	N/A

Summary

Genetic Technologies beats 12144 on 1 of the 1 factors compared between the two stocks.

Genetic Technologies vs. BARD1 Life Sciences Stock

BARD1 Life Sciences (ASX:BD1) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BARD1 Life Sciences and Genetic Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BARD1 Life Sciences	0	0	0	0	N/A
Genetic Technologies	0	0	0	0	N/A

Earnings & Valuation

This table compares BARD1 Life Sciences and Genetic Technologies' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BARD1 Life Sciences	$612,251.00	0.00	$-6,644,706.43	A($0.08)	N/A
Genetic Technologies	$25,714.00	0.00	$-9,016,729.60	A$0.00	N/A

BARD1 Life Sciences has higher revenue and earnings than Genetic Technologies.

Profitability

This table compares BARD1 Life Sciences and Genetic Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BARD1 Life Sciences	N/A	N/A	N/A
Genetic Technologies	N/A	N/A	N/A

Summary

BARD1 Life Sciences beats Genetic Technologies on 2 of the 3 factors compared between the two stocks.

Genetic Technologies vs. Charles River Laboratories International Stock

Genetic Technologies (ASX:GTG) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Genetic Technologies and Charles River Laboratories International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
Charles River Laboratories International	N/A	N/A	N/A

Earnings & Valuation

This table compares Genetic Technologies and Charles River Laboratories International's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$25,714.00	0.00	$-9,016,729.60	A$0.00	N/A
Charles River Laboratories International	N/A	N/A	N/A	N/A	N/A

Charles River Laboratories International has lower revenue, but higher earnings than Genetic Technologies.

Analyst Recommendations

This is a summary of current recommendations for Genetic Technologies and Charles River Laboratories International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0	0	0	0	N/A
Charles River Laboratories International	0	0	0	0	N/A

Summary

Genetic Technologies beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Genetic Technologies vs. Cryosite Stock

Cryosite (ASX:CTE) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cryosite and Genetic Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cryosite	0	0	0	0	N/A
Genetic Technologies	0	0	0	0	N/A

Earnings and Valuation

This table compares Cryosite and Genetic Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cryosite	$9.71 million	0.00	$515,455.60	A$0.01	N/A
Genetic Technologies	$25,714.00	0.00	$-9,016,729.60	A$0.00	N/A

Cryosite has higher revenue and earnings than Genetic Technologies.

Profitability

This table compares Cryosite and Genetic Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cryosite	N/A	N/A	N/A
Genetic Technologies	N/A	N/A	N/A

Summary

Cryosite beats Genetic Technologies on 3 of the 3 factors compared between the two stocks.

Genetic Technologies vs. dorsaVi Stock

dorsaVi (ASX:DVL) and Genetic Technologies (ASX:GTG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Earnings & Valuation

This table compares dorsaVi and Genetic Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
dorsaVi	$1.65 million	0.00	$-3,158,396.93	A($0.01)	N/A
Genetic Technologies	$25,714.00	0.00	$-9,016,729.60	A$0.00	N/A

dorsaVi has higher revenue and earnings than Genetic Technologies.

Analyst Recommendations

This is a summary of recent ratings and price targets for dorsaVi and Genetic Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
dorsaVi	0	0	0	0	N/A
Genetic Technologies	0	0	0	0	N/A

Profitability

This table compares dorsaVi and Genetic Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
dorsaVi	N/A	N/A	N/A
Genetic Technologies	N/A	N/A	N/A

Summary

dorsaVi beats Genetic Technologies on 2 of the 3 factors compared between the two stocks.